Q190706 (Q190706): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Created claim: summary (P836): Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiM...)
(‎Changed label, description and/or aliases in 1 language: remove_english_label)
label / enlabel / en
12012 — MIMEDI

Revision as of 09:29, 13 October 2020

Project in France financed by DG Regio
Language Label Description Also known as
English
No label defined
Project in France financed by DG Regio

    Statements

    0 references
    0 references
    10,211,026.83 Euro
    0 references
    13,614,711.32 Euro
    0 references
    75.0 percent
    0 references
    1 December 2017
    0 references
    30 November 2021
    0 references
    Université de Franche-Comté
    0 references
    Q2537920 (Deleted Item)
    0 references

    47°14'23.03"N, 6°0'44.14"E
    0 references
    25030
    0 references
    Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
    0 references
    Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English)
    13 October 2020
    0 references
    Device for biological element sorting by acoustophoresis. (English)
    Quarroz – FEMTO, Univ-Franche-Comte 2018
    0 references

    Identifiers

    10341
    0 references
    4607
    0 references